

Craig T Wallington-Beddoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5964368/publications.pdf>

Version: 2024-02-01

33
papers

802
citations

623188

14
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

1409
citing authors

#	ARTICLE	IF	CITATIONS
1	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	6.3	188
2	Resistance to proteasome inhibitors and other targeted therapies in myeloma. <i>British Journal of Haematology</i> , 2018, 182, 11-28.	1.2	78
3	Sphingosine Kinase 2 Promotes Acute Lymphoblastic Leukemia by Enhancing <i><i>MYC</i></i> Expression. <i>Cancer Research</i> , 2014, 74, 2803-2815.	0.4	73
4	FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. <i>Autophagy</i> , 2011, 7, 707-715.	4.3	68
5	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 771-782.	0.6	67
6	Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. <i>Cell Death Discovery</i> , 2018, 4, 72.	2.0	50
7	Prognostic and predictive biomarker developments in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 151.	6.9	49
8	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. <i>Oncotarget</i> , 2017, 8, 43602-43616.	0.8	37
9	Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e36429.	1.1	22
10	Sphingolipids and the unfolded protein response. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 1483-1494.	1.2	20
11	Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. <i>Blood</i> , 2022, 139, 3737-3751.	0.6	20
12	Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. <i>Medical Journal of Australia</i> , 2003, 178, 267-271.	0.8	17
13	Failure to Achieve a Threshold Dose of CD34+CD110+ Progenitor Cells in the Graft Predicts Delayed Platelet Engraftment after Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1386-1393.	2.0	17
14	Oncogenic properties of sphingosine kinases in haematological malignancies. <i>British Journal of Haematology</i> , 2013, 161, 623-638.	1.2	17
15	Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. <i>Neoplasia</i> , 2022, 24, 1-11.	2.3	12
16	Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 443-447.	1.2	11
17	Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1050-1065.	2.5	11
18	Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. <i>Molecular Oncology</i> , 2022, 16, 1221-1240.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Novel therapies for multiple myeloma. <i>Aging</i> , 2017, 9, 1857-1858.	1.4	6
20	Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 31-34.	0.7	5
21	Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 713-729.	2.5	5
22	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16â€02 trial. <i>British Journal of Haematology</i> , 2021, 194, 580-586.	1.2	5
23	Enhancing ER stress in myeloma. <i>Aging</i> , 2017, 9, 1645-1646.	1.4	5
24	Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. <i>Biomarker Research</i> , 2018, 6, 6.	2.8	4
25	Resistance Mechanisms to Novel Therapies in Myeloma. , 2019, , .		3
26	Identification of Sphingosine Kinases As Therapeutic Targets in B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1499-1499.	0.6	2
27	Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2021, , 39-59.	0.1	1
28	Targeting sphingosine kinase 2 suppresses MYC expression and kills acute lymphoblastic leukemia cells. <i>Experimental Hematology</i> , 2013, 41, S49.	0.2	0
29	INHIBITION OF SPHINGOSINE KINASE 2 RESENSITISES BORTEZOMIB-RESISTANT MULTIPLE MYELOMA. <i>Experimental Hematology</i> , 2019, 76, S58.	0.2	0
30	CERAMIDE EVOKES AN APOPTOTIC INTEGRATED STRESS RESPONSE IN ACUTE MYELOID LEUKEMIA. <i>Experimental Hematology</i> , 2019, 76, S83.	0.2	0
31	FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death. <i>Blood</i> , 2010, 116, 3260-3260.	0.6	0
32	Sphingosine Kinase Inhibition Has Pre-Clinical Activity in Acute Lymphoblastic Leukemia,. <i>Blood</i> , 2011, 118, 3573-3573.	0.6	0
33	Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1426-1426.	0.6	0